The researchers believe that their prototype could be the basis of a portable, point-of-care testing platform that would enable rapid testing anywhere.
The company said that at a time of unparalleled growth, it is building three new manufacturing lines and expanding resources for future assay development.
Inflammatix said that if its test obtains Emergency Use Authorization next year, clinicians will be able to better gauge the severity of a COVID-19 patient's infection.
The firm said that the shortage of testing in rural America highlights a need for its rapid molecular system, which is small enough to fit in a backpack.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
